Refine by
Testing In Animals Articles & Analysis: Older
37 news found
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. The innovative multi-type animal cognitive behavioral tests are set to complement disease research methodology, enabling scientists to gain deeper insight into the complexities of cognitive functioning and its implications in various pathological conditions. ...
In today’s fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of ...
In a groundbreaking move to revolutionize the field of biomedical research, Alfa Chemistry recently announced the launch of its highly anticipated custom organs-on-chips service. This cutting-edge technology provides scientists and researchers with an innovative platform to study human organs in a way that was previously impossible, promising to accelerate drug discovery, reduce the need for ...
In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development. What can viral vectors be used for? Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors can be used for the treatment of various ...
ByNuvonis
There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals. We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids. ...
Frost & Sullivan recently assessed the artificial intelligence (AI)-enabled preclinical development industry, and, based on its analysis results, recognizes VeriSIM Life with the 2022 North America Competitive Strategy Leadership Award. The company's core mission is to increase human life expectancy through artificial intelligence-driven biosystem simulations and to personalize patient ...
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced it has been selected as the winner of the “Predictive Analytics Solution of the Year" in the BioTech Breakthrough Awards program conducted by BioTech Breakthrough. Biotech Breakthrough is a leading independent ...
Optibrium and Lhasa Limited publish joint peer-reviewed research in the Journal of Medicinal Chemistry, expanding predictive modelling beyond human Cytochrome P450. Study demonstrates novel predictive models for drug metabolism to improve drug design and Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and ...
RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite®, the company’s bone adhesive biomaterial. Dr. Michael R. Norton, ...
Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch of its new B2C e-commerce website, abingdonsimplytest.com. ...
VeriSIM Life (VeriSIM) www.verisimlife.com, a leading artificial intelligence (AI)-enabled company providing services to de-risk R&D decision making for breakthrough drug development, today announced that it has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates. “We are excited to expand our common mission and work with ...
MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model. MatTek Life Sciences, a Boston-area tissue engineering company and a member of the BICO Group, announced today it has entered into a distribution agreement and strategic partnership with Cell4Pharma, a Netherlands-based company specializing ...
MatTek Life Sciences will produce and distribute EpiOral from its production facility in Slovakia, continuing the BICO groups’ focus on providing on-demand tissues to the European market. MatTek Life Sciences, a Boston-area tissue engineering company and a part of the BICO Group, announced today its European facility in Bratislava, Slovakia, will begin producing and shipping EpiOral, a ...
Injectsense Inc., a sensor-enabled digital health company, today announced it has been awarded a two-year, $1.7M Small Business Innovation Research (SBIR) grant from the National Eye Institute of the National Institutes of Health, for the IOP-Connect™ system. IOP-Connect is based on an implantable intra-ocular pressure (IOP) sensor platform smaller than a grain of rice, that for the first ...
Durham, NC (September 16, 2021) – Altis Biosystems, Inc., developer of RepliGut®, a technology platform that produces a layer of primary human intestinal stem and/or differentiated cells of either the small intestine or colon, announced today a Research Funding Initiative focused on one unifying purpose: To accelerate research into complex diseases and aid researchers in unlocking ...
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission. Q2 and Recent Business Highlights: ...
The current approach to seasonal and pandemic flu is akin to a game of Whack-a-Mole. Scientists do their best to anticipate the most likely culprits from a constantly evolving cast of viral characters, hoping that their efforts will land effectively in the coming flu season. Predictions of which influenza strains will be circulating each year are made more than six months before the onset of flu ...
Despite the covid-19 crisis and no mega-rounds of investment in 2020, Biotech start-ups are back at the top! Swiss Biotech startups collected more than CHF 800 million in 2020, an increase of 31% compared to 2019. This is linked to the fact that innovation in drug development is taking place in the long term and, to the constant growing worldwide trend of investments in Biotech. A journey inside ...
Stem Pharm has been awarded a $1.7 million SBIR grant from the National Institute of Environmental Health Sciences of the National Institutes of Health (NIH) to optimize its induced pluripotent stem cell (iPSC)-derived model of the central nervous system for drug discovery and toxicology applications. Stem Pharm’s model fills a commercial need to accurately reflect the complexity of cell ...
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health ...